Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Condition:   Hepatocellular Carcinoma Intervention:   Drug: Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies Sponsor:   Shanghai Zhongshan Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials